Rheumatoid Arthritis, Quality of Life
Conditions
Brief summary
The National Institute of Medical Sciences and Nutrition is a national reference center for rheumatic diseases that belongs to The National Institutes of Health, and has Federal founding. More than 8,000 patients with a wide variety of rheumatologic diagnosis receive medical care. On March 2020, the WHO announced COVID-19 outbreak a pandemic. The first case was registered in Mexico on February 2020. In March 2020, the Mexican Government requested that our Institution should restrict health care to exclusively COVID-19 patients; accordingly, outpatient consultations were, and up to August 2020 still, hold on. Meanwhile, when possible, the Department of Immunology and Rheumatology has implemented an on-demand, non-organized patient´s health care, through email and phone contact; nonetheless, and due to the middle-low socioeconomic status of most of our patients and limited technical resources available at our Institution, the attempt has been challenging.
Detailed description
The aim objective of this project is to explore patients perception about access to medical care and to medications, access to communication with their primary rheumatologist and patients risk perception about COVID-19 disease, for this a survey directed (questionnaire locally developed) will apply and to explore how the reintegration at the usual medical care has a positive impact in the patient´s disease activity, patient´s quality of life and psychopathology (depression, anxiety and posttraumatic stress).
Interventions
OTHERCOVID-19 survey
A questionnaire locally developed to explore access to medical care and to medications, access to communication with their primary rheumatologist, and patients risk perception about COVID-19 disease
OTHERRAPID-3
The instrument measures function, pain, and patient global estimate of status, with correspond to activity disease
OTHERWHOQOL-BREF
The instrument measures the patient´s quality of life (4 dimensions: physics, phycological, social, and environment)
OTHERDASS-21 instrument (depression and anxiety)
The instrument measures the presence of depression and anxiety
OTHERIER-R (posttraumatic stress)
The instrument measures the presence of posttraumatic stress
Sponsors
National Institute of Medical Sciences and Nutrition, Salvador Zubiran
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a rheumatic disease diagnosis according to their primary rheumatologist who agree to participate
Exclusion criteria
* Patients with a not confirmed rheumatic disease * Patients lost to follow-up from the outpatient for \> 1 year period * Patients with pregnancy plans
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the pattern of the usual medical care among the rheumatic disease patients | At study inclusion (The first medical consultation posterior to open the external outpatient's service, post COVID-19 pandemic) | To determinate the proportion of the rheumatic disease patients affected in their usual medical care during the COVID-19 pandemic in our Institution with the COVID-19 survey (locally development) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in the patient's activity disease | In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up | Change in the activity disease measured as RAPID-3 of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 30 a \> number \> disease activity |
| Change in the patient's activity disease measures by their rheumatologist | In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up | Change in the activity disease measured by their rheumatologist (4 questions) of the rheumatic disease patients in a 6 months follow-up. The results will express with 3 categories (without activity, low activity, moderate activity, high activity) |
| Change in patient´s quality of life | In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up | Change in the quality of life measured as WHOQOL-BREF of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 100 a \> number \> quality of life |
| Change in patient´s depression and anxiety | In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up | Change in the psychopathology measured as DASS-21 instrument (depression and anxiety) of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 8 a cut of point \> 8 suggests depression and stress presence, and \> 5 suggests anxiety presence |
| Change in patient´s posttraumatic stress | In the first medical consultation posterior to open the external outpatient's service (post COVID-19 pandemic) to 6 months follow-up | Change in the psychopathology measured as IER-R (posttraumatic stress) of the Rheumatic disease patients in a 6 months follow-up. The results will express with a scale 0 to 88 a cut of point \> 24 would be significant |
Countries
Mexico
Outcome results
None listed